Archive for the ‘Urology / Nephrology’ Category

Stromedix Receives Orphan Drug Designation For STX-100 In Chronic Allograft Nephropathy

Thursday, August 14th, 2008

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the US Food and Drug Administration ("FDA") for the treatment of chronic allograft nephropathy. Chronic allograft nephropathy (CAN), also known ...

Surgical Treatment Of Stress Urinary Incontinence: Options And Surgical Pearls

Wednesday, August 13th, 2008

UroToday.com - Until a decade ago slings were advocated for complicated cases, patients who had failed multiple procedures such as Kelly plications, needle suspensions or retropubic bladder neck suspensions and for patients with recognized intrinsic sphincter dysfunction. A number of publications in the last half of the 90's helped to ...

Medical Management Of Benign Prostatic Hyperplasia (BPH)/Lower Urinary Tract Symptoms (LUTS)

Wednesday, August 13th, 2008

UroToday.com - Benign Prostatic Hyperplasia (BPH) is the most common benign tumor in the aging male. The Symptoms associated with BPH, termed LUTS can be bothersome enough to significantly impact the life of men and their families. While the gold standard for BPH treatment is TURP, over the past 20 ...

Options In Prostate Cancer Surgery: Perineal Prostatectomy In The Age Of Minimally Invasive Surgery

Monday, August 11th, 2008

UroToday.com - In the age of minimally invasive surgery, laparoscopic and robotic assisted laparoscopic prostatectomy has been associated with a substantial increase in operative costs without a significant improvement in outcomes to date. As a result, there has been renewed interest in one of the original approaches to prostate cancer. ...

Pelvic Prolapse: What Does The Urologist Contribute?

Monday, August 11th, 2008

UroToday.com - Any urologist dealing with incontinence in the female patient must deal with pelvic organ prolapse. At a minimum the urologist must evaluate the patient for prolapse and make an appropriate referral to either another urologist or a gynecologist for management. Other degrees of involvement range from evaluation and ...

Overactive Bladder: Management And Treatment Options

Monday, August 11th, 2008

UroToday.com - Overactive Bladder (OAB) is a disease defined by its symptoms, consisting of urgency with or without urge incontinence, frequency and nocturia.1 OAB is a very common problem with an estimated 16 - 33 million sufferers in the US.2The standard treatment of OAB is a combination of behavioral and ...

Urethral Stricture Tips

Monday, August 11th, 2008

UroToday.com - Urologists in practice will likely be confronted with bulbous urethral stricture disease. Certainly there will be other patients who present to the office, but most of the techniques for dealing with strictures, other than in the bulbous urethra, are more than the general urologist in practice may want ...

Medical Management And Surgical Management Of Peyronie’s Disease

Monday, August 11th, 2008

UroToday.com Peyronie's disease is a scarring phenomenon affecting the tunica albuginea of the penis. Scar tissue forms "plaques" that can result in pain with erection, penile deviation, penile shortening, indentation, and/or erectile dysfunction. It is associated with difficulty with sexual intercourse and as such it is associated with loss of ...

Minimally Invasive Surgical Therapy And Lower Urinary Tract Symptoms Treatment Evidence Based Treatment

Monday, August 11th, 2008

UroToday.com - The new paradigm in the treatment of Lower Urinary Tract Symptoms (LUTS) is towards both medical management and minimally invasive surgery. LUTS is a symptom complex that includes both irritative as well as obstructive symptoms. Generally, surgical treatment is directed at the obstructive component. The "gold standard" for ...

Non-Muscle Invasive Transitional Cell Carcinoma

Sunday, August 10th, 2008

UroToday.com - G1-3pTa/1 TCC accounts for up to 80% of all newly diagnosed bladder cancer. Whilst bladder cancer is the 5th commonest cancer it is the most expensive disease to manage because of its propensity to recur and progress. Identifying risk of recurrence and/or progression is essential in order to ...

Penile Prostheses For The Treatment Of Erectile Dysfunction

Sunday, August 10th, 2008

UroToday.com - While erectile dysfunction has been described since ancient times, adequate treatment has only been available for the last three decades. Modern penile prosthetic devices were first developed in the early 1970s when Small et al. along with Scott et al. reported the implantation of penile prosthetic devices into ...

Silent Kidney Disease Tied To Heart Attacks And Early Death, Even Among Young Adults

Sunday, August 10th, 2008

Chronic kidney disease doubles the risk of heartattack, stroke, and early mortality, even among young and middle-agedadults, according to results of a nationwide screening program. Chronic kidney disease is a recognized risk factor for cardiovasculardisease in elderly people. New data from the National KidneyFoundation's Kidney Early Evaluation Program ...

Prostatitis And Inflammatory Conditions Of The Prostate

Sunday, August 10th, 2008

Objectives * Provide an overview of the prostatitis syndromes * Present a practical approach to diagnosis * Summarize current treatment optionsMaterials and MethodsThe recent literature on the prostatitis syndromes was reviewed with particular reference to randomized controlled clinical trials (RCTs). Published ...

PSA Dynamics And Nomograms In The Diagnosis And Treatment Planning For Prostate Cancer

Sunday, August 10th, 2008

UroToday.com - The introduction of PSA as a marker for prostate cancer has dramatically altered how prostate cancer is diagnosed and treated. Along with the improvements in diagnosis and treatment options has come the realization that as men age prostate cancer is relatively common and that not all prostate cancer ...

Renal Cell Carcinoma

Sunday, August 10th, 2008

UroToday.com - Metastatic renal cell carcinoma was once considered to be a disease without significant therapeutic leads. Intravenous administration of interleukin-2 was until recently the only FDA approved treatment for metastatic renal cell carcinoma. Interleukin-2 at best results in durable complete responses in less than 10% of patients. Considerable toxicity ...